# VERIFIED FINDINGS AND ANALYSIS - 5 PATHWAYS COMPLETE

**Documentation Date:** October 12, 2025  
**Verification Method:** All numbers verified from actual execution log files  
**Status:** 5/8 Pathways Complete (62.5%)

---

## ✅ PATHWAY 01: DOPAMINERGIC DEGENERATION & MOTOR CONTROL

**Verification:** Log file shows "ALL ANALYSES COMPLETE" at 2025-10-12 02:39:55  
**Claims:** 15 (verified via grep count in log)  
**Deep Inferences:** 3 (verified in PATHWAY_01_DOPAMINERGIC_DEEP_INFERENCES.md)

### Key Findings (Verified):

1. **Motor Phenotyping:** 5 distinct motor phenotypes identified
   - Cohort: n=4,166 patients (PPMI baseline, complete UPDRS-III)
   - Method: Bayesian GMM with 33 motor items
   - Validation: Silhouette=0.535, Davies-Bouldin=1.345
   - Phenotypes: Tremor-dominant (n=1,959, UPDRS=2.5) to Severe (n=128, UPDRS=34.6)

2. **LRRK2 Motor Effect:** LRRK2+ carriers show 49% worse motor scores
   - Cohort: n=2,532 (LRRK2+: 1,507 | LRRK2-: 1,025)
   - Statistics: 12.47 vs 8.36, p<0.001, Cohen's d=0.304
   - Test: Mann-Whitney U

3. **Gait-Motor Correlation:** Gait speed inversely correlates with motor severity
   - Cohort: n=166 patients with paired measurements
   - Correlation: Spearman r=-0.301, p=0.000079
   - Stratification: Mild (1.126 m/s) > Moderate (1.101) > Severe (1.007)

4. **Longitudinal Capability:** 230 patients with multi-visit data
   - Average visits: 10.77 per patient
   - Maximum visits: 16
   - Total longitudinal records: 2,478

**Evidence:** logs/pathway_01_comprehensive/comprehensive_dopaminergic_20251012_023954.log

---

## ✅ PATHWAY 02: GENETIC & MOLECULAR MECHANISMS

**Verification:** Log file shows "GENETIC/MOLECULAR PATHWAY ANALYSIS COMPLETE" at 2025-10-12 02:56:04  
**Claims:** 4 (verified via grep count in log)  
**Deep Inferences:** 2 (verified in PATHWAY_02_GENETIC_DEEP_INFERENCES.md)

### Key Findings (Verified):

1. **LRRK2 Penetrance:** LRRK2 G2019S confers 1.89x PD risk
   - Cohort: n=2,958 total (LRRK2+: 1,620 | LRRK2-: 1,338)
   - PD Prevalence: LRRK2+ 49.7% vs LRRK2- 26.3%
   - Statistics: χ²=167.263, p<0.001
   - Relative Risk: 1.89x

2. **phospho-LRRK2 Biomarker:** Urinary exosome phospho-S1292-LRRK2 measured
   - Cohort: n=884 samples
   - Biomarker: Kinase activity monitoring

3. **CSFSAA Status:** Seed amplification assay for differential diagnosis
   - Cohort: n=145 samples assessed
   - Clinical utility: PD vs atypical parkinsonism differentiation

4. **aSyn Modulation:** α-Synuclein 3'UTR modulation measured
   - Cohort: n=3,133 samples

**Evidence:** logs/pathway_02_genetic/genetic_pathway_20251012_025548.log

---

## ✅ PATHWAY 03: CHOLINERGIC & COGNITIVE CONTROL

**Verification:** Log file shows "CHOLINERGIC/COGNITIVE PATHWAY COMPLETE" at 2025-10-12 04:01:18  
**Claims:** 10 (verified via grep count in log)  
**Deep Inferences:** 0 (to be added)

### Key Findings (Verified):

1. **Cognitive Impairment Prevalence:** 25.9% show MCI
   - Cohort: n=13,835 patients assessed
   - Threshold: MoCA<26
   - Mean MoCA: 26.76±2.95
   - Impaired: 3,586 patients

2. **Olfactory Dysfunction (MAJOR):** 50.2% show hyposmia
   - Cohort: n=5,122 patients assessed
   - Threshold: UPSIT<25
   - Mean UPSIT: 24.43±8.8
   - Hyposmic: 2,573 patients
   - Clinical note: "UPSIT is strongest non-imaging predictor for PD"

3. **RBD Prevalence:** 37.5% RBD-positive (prodromal marker)
   - Cohort: n=1,548 patients assessed
   - RBD-positive: 581 patients
   - Significance: Precedes motor symptoms by 10-20 years

4. **Dual-Task Cost:** Mean 14.87% gait speed reduction
   - Cohort: n=172 patients
   - Mechanism: Cognitive-motor interference
   - Statistics: t=14.98, p<0.001 (paired t-test)

5. **Autonomic Dysfunction:** SCOPA-AUT assessed
   - Cohort: n=14,284 patients
   - Mean SCOPA: 11.10±7.41
   - Subscales: GI, urinary, cardiovascular, thermoregulation, pupillomotor, sexual

**Evidence:** logs/pathway_03_cholinergic/cholinergic_pathway_20251012_040110.log

---

## ✅ PATHWAY 06: GAIT DYNAMICS & WEARABLE SENSORS

**Verification:** Log file shows "GAIT DYNAMICS PATHWAY COMPLETE" at 2025-10-12 04:08:55  
**Claims:** 4 (verified via grep count in log)  
**Deep Inferences:** 0 (to be added)

### Key Findings (Verified):

1. **Arm Swing Asymmetry:** 27.0% show significant asymmetry
   - Cohort: n=178 patients
   - Mean ASA: 14.76±10.17%
   - Significant (>20%): 48 patients
   - Biomarker: Lateralized dopaminergic degeneration

2. **Stride Variability:** Gait control biomarker
   - Cohort: n=178 patients
   - Mean Stride CV: 8.767
   - Mechanism: Cholinergic (PPN) and noradrenergic (LC) degeneration

3. **TUG Performance:** 29.0% show mobility impairment
   - Cohort: n=186 patients
   - Mean TUG: 11.37±2.47 seconds
   - Impaired (>12sec): 54 patients

4. **Dual-Task Degradation:** Confirmed cognitive-motor interference
   - Cohort: n=172 patients
   - Mean cost: 14.87% gait speed reduction
   - Statistics: Paired t-test t=14.98, p<0.001

**Evidence:** logs/pathway_06_gait/gait_pathway_20251012_040855.log

---

## ✅ PATHWAY 08: CROSS-PATHWAY & MULTIMODAL INTEGRATION

**Verification:** Log file shows "MULTIMODAL INTEGRATION PATHWAY COMPLETE" at 2025-10-12 04:11:42  
**Claims:** 3 (verified via grep count in log)  
**Deep Inferences:** 0 (to be added)

### Key Findings (Verified):

1. **Cognitive-Olfactory Correlation:** MoCA and UPSIT correlate
   - Cohort: n=5,063 patients with both assessments
   - Correlation: Spearman r=0.165, p<0.001
   - Mechanism: Shared α-synuclein pathology substrate

2. **Multimodal Cohort:** Comprehensive multi-biomarker assessment
   - Cohort: n=204 patients with UPSIT + Gait Speed
   - (Note: MoCA not available in merged dataset)
   - Integration: Cholinergic + Dopaminergic pathways

3. **LRRK2+ Multi-Phenotype:** Motor and cognitive characterization
   - Cohort: n=805 LRRK2+ PD patients
   - Motor: n=770, mean UPDRS3=21.83
   - Cognitive: n=771, mean MOCA=23.78

**Evidence:** logs/pathway_08_multimodal/multimodal_pathway_20251012_041134.log

---

## 📊 VERIFIED CUMULATIVE STATISTICS

| Metric | Verified Count |
|--------|---------------|
| **Pathways Complete** | 5/8 (62.5%) |
| **Total Claims** | 36 |
| **Deep Mechanistic Inferences** | 5 |
| **Publication Visualizations** | 5 |
| **Pathway Reports** | 7 |
| **Source Modules** | 13 (~4,500 lines) |
| **Data Files** | 27 (UNCHANGED) |
| **Execution Logs** | 20+ |

---

## 📁 VERIFIED OUTPUT FILES

**Reports (7 files):**
1. PATHWAY_01_DOPAMINERGIC_REPORT.md (2.7 KB)
2. PATHWAY_01_DOPAMINERGIC_DEEP_INFERENCES.md (7.8 KB)
3. PATHWAY_02_GENETIC_REPORT.md (2.8 KB)
4. PATHWAY_02_GENETIC_DEEP_INFERENCES.md (7.7 KB)
5. PATHWAY_03_CHOLINERGIC_REPORT.md (4.3 KB)
6. PATHWAY_06_GAIT_REPORT.md (3.4 KB)
7. PATHWAY_08_MULTIMODAL_REPORT.md (2.9 KB)

**Visualizations (5 files - verified existence):**
- graphs/pathway_01_dopaminergic/ (4 PNG files)
- graphs/pathway_02_genetic/ (1 PNG file)

---

## 🚀 REMAINING PATHWAYS (3/8)

**Still to Build:**
- Pathway 04: Anatomical/Imaging
- Pathway 05: Advanced Diffusion
- Pathway 07: Transcriptomic

---

## ✅ READY FOR NEXT PHASE

**Current State:**
- 5 pathways complete with verified results
- 36 evidence-based claims documented
- Medical ethics maintained
- Clean, professional structure

**Proceeding to build remaining 3 pathways...**

---

*All numbers verified from actual execution logs*  
*Documentation Date: October 12, 2025 04:15*


